Tagged with EG

CNS Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research.   What have been some of the biggest successes in the last three to four years for this affiliate? The greatest…

generics  Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth in the future.   You are currently the Vice President of CAPGEN; could you please tell us a bit about…

innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients.   You have had…

Boston Consulting Group The managing director of Boston Consulting Group Malaysia discusses the gap between public and private healthcare in the country, and what can be done to bridge it.   What appears to be a focus for many companies now is bridging the gap between the private healthcare sector and the public…

pricing Cho Chan-Hwui, president of the Korean Pharmaceutical Association (KPA), discusses the major hurdles that pharmacists in Korea must overcome today, and the increased focus on prescription by INN.   How successfully has the policy stipulating the separation of prescription and dispensing (SPD) worked over the last 15 years? Complete success…

innovation Dr. Jung Yun-Taek, head researcher of the pharmaceutical division at the Korea Health Industry Development Institute (KHIDI), discusses the real potential that Korean pharmaceutical companies offer to the rest of the world for disruptive and incremental innovation.   What are the current trends in Korea’s pharmaceutical industry? The global market…

advisory Nicola Carusoni, PwC’s lead pharmaceutical partner in Buenos Aires, gives an overview of the key trends in the Argentinian pharma industry and discusses the importance of PwC as a partner to the industry given the current economic context.   What are the key trends in the Argentinian pharmaceutical market at present? The…

doing business Montse Planas was appointed as General Manager of Fresenius Kabi Spain just as the financial crisis went into a downward spin. Today she discusses the efforts the company made to respond to the crisis, and ways in which cost-cutting could be implemented in Spain.   What were some of the…

development Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations.    How did you become part of Glenmark, and what was your main objective when you took the helm in Argentina? I joined Glenmark five years ago as…

family business President of the company, Alberto Alvarez-Saavedra, discusses the company’s transformation into a professional organization, and the strategy which has driven remarkable growth in recent years, and will continue to do so as they expand across the region. What have been your main achievements since you took over as the President of…

association On behalf of the chamber of industry that represents research-based pharma and biopharma companies in Argentina, Ernesto Felicio discusses the current challenges facing the industry, and the chambers current agenda for change.   To what extent has the environment for multinationals, or their role in the Argentinian pharmaceutical industry, significantly…

regulation In July 2012 COFEPRIS (the Federal Commission for the Protection against Sanitary Risk) was recognized as a national regulatory authority of regional reference by the PAHO (Pan-American Health Organization), opening the doors to exports for the Mexican pharmaceutical industry. The executive director of the association representing domestic drug manufacturers discusses…